ERBB2 and melanoma: In our experiment, although the expression of HER2 in melanoma cells was not very strong, HER2Bi-armed ATC showed significant anti-proliferative and cytotoxic activity, which indicated that development of bispecific antibodies would be benefit in the field of targeting therapeutics.